Response to Hepatic Arterial Infusion Chemotherapy Combined with Camrelizumab and Targeted Therapy in Advanced Primary Hepatic Neuroendocrine Carcinoma: a Case Report and Literature Review

Overview

Journal J Gastrointest Oncol

Date 2024 Sep 16

PMID 39279984

Authors

Xianmao Shi

Ze Su

Zhiyin Liang

Xing Sun

Jinwu Luo

Zhongrong Long

Hongmian Jiang

Jonathan Strosberg

Ravi Kumar Paluri

Yi Xiao

Affiliations

Soon will be listed here.

Abstract

Background: Primary hepatic neuroendocrine carcinoma (PHNEC), which often lacks distinctive radiological features or specific clinical symptoms, is extremely rare. In this report, we describe a rare case of PHNEC that was successfully treated with hepatic arterial infusion chemotherapy (HAIC) combined with camrelizumab and targeted therapy.

Case Description: This report describes the treatment of a 53-year-old male with PHNEC in China. The patient was admitted for persistent upper right quadrant abdominal pain. Dynamic contrast-enhanced abdominal computed tomography (CT) and magnetic resonance imaging (MRI) both detected multiple masses, enlarged portal lymph nodes, and retroperitoneal lymph nodes. Histological and immunohistochemistry of the largest mass biopsy specimen from the right liver lobe confirmed the neuroendocrine tumor of the liver. The patient underwent HAIC with a modified fluorouracil and oxaliplatin (mFOLFOX) regimen. Meanwhile, the patient received camrelizumab (200 mg, intravenously, q3w) apatinib (250 mg, oral, daily) within 7 days after the start of HAIC. CT and MRI showed a marked decrease in the size of the largest mass of the liver and the portal lymph nodes, indicating a partial response of the tumor.

Conclusions: PHNEC is a very rare tumor, and the treatment for its advanced type is controversial and remains to be standardized. HAIC combined with camrelizumab and targeted therapy may be an effective and safe therapeutic option for patients with PHNEC.

References

Qi R, Yang W, Zhu S, Mao J, Yang B, Xu A . Transcatheter arterial chemoembolization of apatinib and camrelizumab (SHR1210) against liver metastasis from hepatic neuroendocrine tumor: a case report. Front Oncol. 2024; 14:1278340. PMC: 10880017. DOI: 10.3389/fonc.2024.1278340. View

Cai Z, He C, Zhao C, Lin X . Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Front Oncol. 2021; 11:611118. PMC: 8047640. DOI: 10.3389/fonc.2021.611118. View

Wang X, Yu J, Yang M, Liu L, Gao J, Ren Y . Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202). Am J Cancer Res. 2020; 10(3):987-996. PMC: 7136926. View

Huang Y, Xu F, Yang J, Huang B . Primary hepatic neuroendocrine carcinoma: clinical analysis of 11 cases. Hepatobiliary Pancreat Dis Int. 2010; 9(1):44-8. View

Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y . Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(11):1500-1512. DOI: 10.1016/S1470-2045(20)30496-4. View

Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J . Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020; 26(10):2337-2345. DOI: 10.1158/1078-0432.CCR-19-4000. View

De Raffele E, Mirarchi M, Cuicchi D, Lecce F, Casadei R, Ricci C . Simultaneous colorectal and parenchymal-sparing liver resection for advanced colorectal carcinoma with synchronous liver metastases: Between conventional and mini-invasive approaches. World J Gastroenterol. 2020; 26(42):6529-6555. PMC: 7673966. DOI: 10.3748/wjg.v26.i42.6529. View

Xu J, Shen L, Bai C, Wang W, Li J, Yu X . Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(11):1489-1499. DOI: 10.1016/S1470-2045(20)30493-9. View

Peifer M, Fernandez-Cuesta L, Sos M, George J, Seidel D, Kasper L . Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44(10):1104-10. PMC: 4915822. DOI: 10.1038/ng.2396. View

10.

Huang H, Jin P, Yang H, Zhang C, Zhang X, Wang J . Primary Hepatic Neuroendocrine Tumor Mimicking Ruptured Hepatocellular Carcinoma with AFP Elevation: A Case Report and Literature Review. Onco Targets Ther. 2020; 13:975-979. PMC: 7007302. DOI: 10.2147/OTT.S236728. View

11.

Li X, Ma Q, Chang C, Li H, Cao D . First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. Front Oncol. 2022; 12:958905. PMC: 9524149. DOI: 10.3389/fonc.2022.958905. View

12.

Qiu M, Chen Y, Bi N, Yang S, He X, Xiong Z . Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas. Dis Markers. 2018; 2018:9191639. PMC: 6207894. DOI: 10.1155/2018/9191639. View

13.

Mehnert J, Bergsland E, ONeil B, Santoro A, Schellens J, Cohen R . Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020; 126(13):3021-3030. DOI: 10.1002/cncr.32883. View

14.

Patel S, Othus M, Chae Y, Giles F, Hansel D, Paul Singh P . A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020; 26(10):2290-2296. PMC: 7231627. DOI: 10.1158/1078-0432.CCR-19-3356. View

15.

Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X . Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. Cardiovasc Intervent Radiol. 2020; 43(7):996-1005. DOI: 10.1007/s00270-019-02406-3. View

16.

Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G . Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022; 7(2):100408. PMC: 9161394. DOI: 10.1016/j.esmoop.2022.100408. View

17.

Sotiropoulos G, Charalampoudis P, Delladetsima I, Stamopoulos P, Dourakis S, Kouraklis G . Surgery for giant primary neuroendocrine carcinoma of the liver. J Gastrointest Surg. 2013; 18(4):839-41. DOI: 10.1007/s11605-013-2346-7. View

18.

Kim S, Ha S, Lee S, Ahn S, Lee J, Park S . The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016; 7(5):484-9. PMC: 4780123. DOI: 10.7150/jca.13711. View

19.

Strosberg J, Mizuno N, Doi T, Grande E, Delord J, Shapira-Frommer R . Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020; 26(9):2124-2130. PMC: 7811789. DOI: 10.1158/1078-0432.CCR-19-3014. View

20.

Fernandez-Ferreira R, Romero-Lopez U, Robles-Avina J, Rivas-Mendoza U, Gonzalez-Camacho C, Valero-Gomez A . Primary Hepatic Neuroendocrine Carcinoma with Metastasis to the Mesentery: A Case Report. Case Rep Oncol. 2023; 16(1):681-697. PMC: 10625823. DOI: 10.1159/000533199. View